{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Bogdanski AM"],"pubmed_abstract":["<h4>Objectives</h4>New methods are needed to detect pancreatic ductal adenocarcinoma (PDAC) earlier to improve outcomes. We previously reported that a panel of protein N-glycosylation traits (NGTs) discriminated PDAC from healthy-controls with an area under the curve (AUC) of 0.81-0.88. However, it remained unclear whether this panel accurately differentiates PDAC from other benign pancreatic disorders. Our study aims to evaluate the performance of the NGT panel in combination with CA19-9, in a diverse cohort, including PDAC cases, healthy-controls and controls with benign pancreatic disorders.<h4>Methods</h4>Protein N-glycosylation profiles were determined in plasma samples using an in-house developed mass spectrometry assay. CA19-9 levels were measured using routine immunoassay test. Res"],"journal":["Pancreas"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12419019"],"repository":["biostudies-literature"],"pubmed_title":["Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases."],"pmcid":["PMC12419019"],"pubmed_authors":["Ballieux BEPB","Cobbaert CM","Clift KE","Mesker WE","Klatte DCF","Wallace MB","van der Burgt YEM","van Leerdam ME","van Hooft JE","Bogdanski AM","Wuhrer M","Bi Y"],"additional_accession":[]},"is_claimable":false,"name":"Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases.","description":"<h4>Objectives</h4>New methods are needed to detect pancreatic ductal adenocarcinoma (PDAC) earlier to improve outcomes. We previously reported that a panel of protein N-glycosylation traits (NGTs) discriminated PDAC from healthy-controls with an area under the curve (AUC) of 0.81-0.88. However, it remained unclear whether this panel accurately differentiates PDAC from other benign pancreatic disorders. Our study aims to evaluate the performance of the NGT panel in combination with CA19-9, in a diverse cohort, including PDAC cases, healthy-controls and controls with benign pancreatic disorders.<h4>Methods</h4>Protein N-glycosylation profiles were determined in plasma samples using an in-house developed mass spectrometry assay. CA19-9 levels were measured using routine immunoassay test. Res","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T01:01:54.347Z","creation":"2026-05-24T03:07:36.603Z"},"accession":"S-EPMC12419019","cross_references":{"pubmed":["40403287"],"doi":["10.1097/MPA.0000000000002517"]}}